CA2615137A1 - Dispositif therapeutique monocouche a liberation controlee - Google Patents

Dispositif therapeutique monocouche a liberation controlee Download PDF

Info

Publication number: CA2615137A1
Authority: CA; Canada
Prior art keywords: spheres; release; therapeutic system; controlled release; single layered
Prior art date: 2007-12-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002615137A

Other languages

English (en)

Inventor

Rasik Patel

Naresh Talwar

Vinayak Pathak

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Pharmascience Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-17

Filing date

2007-12-17

Publication date

2009-06-17

2007-12-17 Application filed by Pharmascience Inc filed Critical Pharmascience Inc

2007-12-17 Priority to CA002615137A priority Critical patent/CA2615137A1/fr

2008-12-15 Priority to PCT/CA2008/002165 priority patent/WO2009076754A1/fr

2008-12-15 Priority to CA2706730A priority patent/CA2706730C/fr

2009-06-17 Publication of CA2615137A1 publication Critical patent/CA2615137A1/fr

Status Abandoned legal-status Critical Current

Links

230000001225 therapeutic effect Effects 0.000 title description 11
238000013270 controlled release Methods 0.000 title description 7
239000003795 chemical substances by application Substances 0.000 description 17
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 16
239000011159 matrix material Substances 0.000 description 16
238000000034 method Methods 0.000 description 13
239000000203 mixture Substances 0.000 description 13
239000008186 active pharmaceutical agent Substances 0.000 description 12
238000000576 coating method Methods 0.000 description 12
239000006185 dispersion Substances 0.000 description 12
-1 polyethylene Polymers 0.000 description 12
239000011248 coating agent Substances 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
229960002024 galantamine hydrobromide Drugs 0.000 description 11
229920000642 polymer Polymers 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 10
150000003839 salts Chemical class 0.000 description 10
235000002639 sodium chloride Nutrition 0.000 description 10
229920003161 Eudragit® RS 30 D Polymers 0.000 description 9
239000002775 capsule Substances 0.000 description 9
238000003756 stirring Methods 0.000 description 9
229920000168 Microcrystalline cellulose Polymers 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000013543 active substance Substances 0.000 description 8
230000000181 anti-adherent effect Effects 0.000 description 8
239000003911 antiadherent Substances 0.000 description 8
229940075614 colloidal silicon dioxide Drugs 0.000 description 8
229960003980 galantamine Drugs 0.000 description 8
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 8
235000019813 microcrystalline cellulose Nutrition 0.000 description 8
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 7
239000011324 bead Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
238000012545 processing Methods 0.000 description 7
239000008213 purified water Substances 0.000 description 7
239000007921 spray Substances 0.000 description 7
239000001069 triethyl citrate Substances 0.000 description 7
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 7
235000013769 triethyl citrate Nutrition 0.000 description 7
239000011230 binding agent Substances 0.000 description 6
235000010980 cellulose Nutrition 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
239000000463 material Substances 0.000 description 6
239000011148 porous material Substances 0.000 description 6
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000010410 layer Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000002202 Polyethylene glycol Substances 0.000 description 4
239000000544 cholinesterase inhibitor Substances 0.000 description 4
239000011247 coating layer Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
125000005396 acrylic acid ester group Chemical group 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
238000013265 extended release Methods 0.000 description 2
229920000578 graft copolymer Polymers 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000004014 plasticizer Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000002356 single layer Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000364027 Sinoe Species 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 description 1
PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229960004302 ambenonium chloride Drugs 0.000 description 1
DXUUXWKFVDVHIK-UHFFFAOYSA-N ambenonium chloride Chemical compound [Cl-].[Cl-].C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl DXUUXWKFVDVHIK-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
229920001531 copovidone Polymers 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000004815 dispersion polymer Substances 0.000 description 1
229960001446 distigmine Drugs 0.000 description 1
GJHSNEVFXQVOHR-UHFFFAOYSA-L distigmine bromide Chemical compound [Br-].[Br-].C=1C=C[N+](C)=CC=1OC(=O)N(C)CCCCCCN(C)C(=O)OC1=CC=C[N+](C)=C1 GJHSNEVFXQVOHR-UHFFFAOYSA-L 0.000 description 1
239000012055 enteric layer Substances 0.000 description 1
229950010753 eptastigmine Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
229920000591 gum Polymers 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
229940088644 n,n-dimethylacrylamide Drugs 0.000 description 1
YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229960001685 tacrine Drugs 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002615137A 2007-12-17 2007-12-17 Dispositif therapeutique monocouche a liberation controlee Abandoned CA2615137A1 (fr)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CA002615137A CA2615137A1 (fr)	2007-12-17	2007-12-17	Dispositif therapeutique monocouche a liberation controlee
PCT/CA2008/002165 WO2009076754A1 (fr)	2007-12-17	2008-12-15	Système thérapeutique à libération contrôlée à monocouche
CA2706730A CA2706730C (fr)	2007-12-17	2008-12-15	Systeme therapeutique a liberation controlee a monocouche

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002615137A CA2615137A1 (fr)	2007-12-17	2007-12-17	Dispositif therapeutique monocouche a liberation controlee

Publications (1)

Publication Number	Publication Date
CA2615137A1 true CA2615137A1 (fr)	2009-06-17

Family

ID=40792428

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA002615137A Abandoned CA2615137A1 (fr)	2007-12-17	2007-12-17	Dispositif therapeutique monocouche a liberation controlee
CA2706730A Expired - Fee Related CA2706730C (fr)	2007-12-17	2008-12-15	Systeme therapeutique a liberation controlee a monocouche

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CA2706730A Expired - Fee Related CA2706730C (fr)	2007-12-17	2008-12-15	Systeme therapeutique a liberation controlee a monocouche

Country Status (2)

Country	Link
CA (2)	CA2615137A1 (fr)
WO (1)	WO2009076754A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2356984A1 (fr) *	2010-02-04	2011-08-17	Nycomed Austria GmbH	Formulation améliorée de bromure de distigmine
ES2938609T3 (es)	2017-09-20	2023-04-13	Tillotts Pharma Ag	Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
CN109464703B (zh) *	2018-11-29	2021-02-26	浙江瑞谷生物科技有限公司	一种骨修复材料及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE426548B (sv) *	1978-12-05	1983-01-31	Haessle Ab	Fast farmaceutisk beredning innehallande en terapeutiskt effektiv hjertglykosid och en polymer
US4758437A (en) *	1981-12-23	1988-07-19	Yamanouchi Pharmaceutical Co., Ltd.	Composition for long acting nicardipine preparation and process of producing the composition
CA1338596C (fr) *	1988-09-27	1996-09-17	Hiroyoshi Koyama	Granules possedant un noyau et leur production
EP0452862B1 (fr) *	1990-04-18	1995-07-19	Asahi Kasei Kogyo Kabushiki Kaisha	Noyaux des germes sphériques, granules sphériques et procédé de leur préparation
DE69912311T2 (de) *	1998-12-24	2004-07-29	Janssen Pharmaceutica N.V.	Galantamin-zusammensetzung mit gesteuerter freisetzung
DE10353196A1 (de) *	2003-11-13	2005-06-16	Röhm GmbH & Co. KG	Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
JP2008534531A (ja) *	2005-03-29	2008-08-28	エボニックレームゲゼルシャフトミットベシュレンクテルハフツング	調節物質の送達に影響を及ぼすマトリックスを有するペレットを有する多粒子の医薬剤形

2007
- 2007-12-17 CA CA002615137A patent/CA2615137A1/fr not_active Abandoned
2008
- 2008-12-15 WO PCT/CA2008/002165 patent/WO2009076754A1/fr active Application Filing
- 2008-12-15 CA CA2706730A patent/CA2706730C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2009076754A1 (fr)	2009-06-25
CA2706730C (fr)	2016-10-18
CA2706730A1 (fr)	2009-06-25

Legal Events

Date	Code	Title	Description
2010-12-17	FZDE	Discontinued
2023-10-30	FZDE	Discontinued	Effective date: 20101217

Publication	Publication Date	Title
EP0377518B1 (fr)	1996-02-07	Composition pharmaceutique à libération retardée
KR101157220B1 (ko)	2012-07-09	리팍시민을 포함하는 위내성 약학적 제제
KR101752014B1 (ko)	2017-06-28	고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
JP4991072B2 (ja)	2012-08-01	時限拍動性薬物送達システム
US7029701B2 (en)	2006-04-18	Composition for the treatment and prevention of ischemic events
EP1005863A1 (fr)	2000-06-07	Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
EP1064937A1 (fr)	2001-01-03	Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
JPH04224517A (ja)	1992-08-13	標的制御釈放薬剤
EP1978935B1 (fr)	2015-01-07	Formules enrobées
JP2002532425A (ja)	2002-10-02	新規な医薬製剤
US5277916A (en)	1994-01-11	Tetracycline dosage form
IE900862L (en)	1990-09-10	A drug-release controlling coating material for long acting¹formulations
US20100280035A1 (en)	2010-11-04	Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier
CA3021071A1 (fr)	2017-10-26	Compositions pharmaceutiques orales de mesalazine
PL192273B1 (pl)	2006-09-29	Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej
WO2004071374A2 (fr)	2004-08-26	Compositions pharmaceutiques d'administration orale une fois par jour
EP2533766B1 (fr)	2013-05-15	Mini-comprimés pharmaceutiques à libération prolongée d'acétate de flécaïnide
WO2011119477A2 (fr)	2011-09-29	Compositions pharmaceutiques à base de sels de carvédilol et leur procédé de préparation
JPH0710745A (ja)	1995-01-13	放出開始時間制御型腸デリバリー経口製剤
CA2706730C (fr)	2016-10-18	Systeme therapeutique a liberation controlee a monocouche
US20080118554A1 (en)	2008-05-22	Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
AU2016255302B2 (en)	2021-03-04	Rivastigmine-containing sustained-release pharmaceutical composition
WO2009065130A2 (fr)	2009-05-22	Formulations à libération modifiée de diltiazème
EP3796908B1 (fr)	2023-05-10	Formulations de propivérine à libération contrôlée
AU6224699A (en)	2000-10-09	Taste masking coating compositions